Rare diseases, defined variably by global regions, collectively impact approximately
300 million individuals despite affecting small population segments individually.
Historically there were no treatments developed for these conditions, leading to significant
care challenges. Public interventions have incentivized treatment development, yet
up to this day, many rare disease patients are deprived of timely diagnosis and treatment
in comparison to patients with more common diseases. This study evaluates the challenges
that rare disease patients and healthcare systems face in the Middle East and North
Africa (MENA), seeking strategies to enhance treatment accessibility.
